Search Results - "KEANE, William F"

Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of Atherosclerosis by Keane, William F, Tomassini, Joanne E, Neff, David R

“…Cardiovascular disease is increased in patients with chronic kidney disease (CKD) and is the principle cause of morbidity and mortality in these patients. In…”
Get full text

Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy: The RENAAL Study by Keane, William F, Zhang, Zhongxin, Lyle, Paulette A, Cooper, Mark E, de Zeeuw, Dick, Grunfeld, Jean-Pierre, Lash, James P, McGill, Janet B, Mitch, William E, Remuzzi, Giuseppe, Shahinfar, Shahnaz, Snapinn, Steven M, Toto, Robert, Brenner, Barry M

“…Diabetic nephropathy is the most important cause of ESRD. The aim of this study was to develop a risk score from risk predictors for ESRD, with and without…”
Get full text

Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables by Maki, Kevin C., PhD, FNLA, Bobotas, George, PhD, Dicklin, Mary R., PhD, Huebner, Margie, Keane, William F., MD

“…Background Long-chain omega-3 fatty acid concentrate pharmaceuticals are used in the United States for treatment of severe hypertriglyceridemia (≥500 mg/dL)…”
Get full text

The role of lipids in renal disease: Future challenges by Keane, William F.

“…The role of lipids in renal disease: future challenges. Experimental studies have provided in vivo and in vitro data to support the notion that dyslipidemia…”
Get full text

Early detection of kidney disease in community settings: the kidney early evaluation program (KEEP) by Brown, Wendy Weinstock, Peters, Rosalind M, Ohmit, Suzanne E, Keane, William F, Collins, Allan, Chen, Shu-Chen, King, Karren, Klag, Michael J, Molony, Donald A, Flack, John M

“…Early identification of persons at risk for kidney disease provides an opportunity to prevent or delay its progression and decrease morbidity and mortality…”
Get full text

The missing link: The parental voice in Bring Your Own Device (BYOD) programs by Keane, Therese, Keane, William F.

“…This paper reports on the parental perspective on one school’s implementation of a Bring Your Own Device (BYOD) Program to ensure students had access to a…”
Get full text

Beyond traditional literacy: Learning and transformative practices using ICT by Keane, Therese, Keane, William F., Blicblau, Aaron S.

“…Educators, government bodies and employers have acknowledged the need for modern learners to acquire 21st century skills using information and communication…”
Get full text

Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure by Nemoto, Takashi, Burne, Melissa J., Daniels, Frank, O'Donnell, Michael P., Crosson, John, Berens, Kurt, Issekutz, Andrew, Kasiske, Bertram L., Keane, William F., Rabb, Hamid

“…Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. The pathophysiologic and potential therapeutic role of selectins in…”
Get full text

Parents’ expectations, perceptions and concerns when schools implement a 1:1 program by Keane, Therese, Keane, William F.

“…Implementing successful one-to-one computer programs where all students have access to mobile devices throughout the school day requires major stakeholders…”
Get full text

Identification of persons at high risk for kidney disease via targeted screening: The NKF Kidney Early Evaluation Program by Brown, Wendy W., Collins, Allan, Chen, Shu-Cheng, King, Karren, Molony, Donald, Gannon, Monica R., Politoski, Gigi, Keane, William F.

“…Identification of persons at high risk for kidney disease via targeted screening: The NKF Kidney Early Evaluation Program. More than 340,000 individuals were…”
Get full text

Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure by Nemoto, Takashi, Yokota, Naoko, Keane, William F., Rabb, Hamid

“…Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. The anemia associated with acute renal failure (ARF) is currently treated…”
Get full text

Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy : Post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) trial by EIJKELKAMP, Wouter B. A, ZHONGXIN ZHANG, DE ZEEUW, Dick, REMUZZI, Giuseppe, PARVING, Hans-Henrik, COOPER, Mark E, KEANE, William F, SHAHINFAR, Shahnaz, GLEIM, Gilbert W, WEIR, Matthew R, BRENNER, Barry M

“…Albuminuria reduction could be renoprotective in hypertensive patients with diabetic nephropathy. However, the current use of renin-angiotensin-system…”
Get full text

Metabolic pathogenesis of cardiorenal disease by Keane, William F.

“…Clinical data have established microalbuminuria/proteinuria as an independent risk factor for the development and progression of renal disease in patients with…”
Get full text

Effect of LDL Cholesterol and Treatment With Losartan on End-Stage Renal Disease in the RENAAL Study by Tershakovec, Andrew M, Keane, William F, Zhang, Zhongxin, Lyle, Paulette A, Appel, Gerald B, McGill, Janet B, Parving, Hans-Henrik, Cooper, Mark E, Shahinfar, Shahnaz, Brenner, Barry M

“…Renal pathology and dyslipidemia commonly coexist. Treatments that lower albuminuria/proteinuria may lower lipids, but it is not known whether lipid lowering…”
Get full text

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy by de Zeeuw, Dick, Remuzzi, Giuseppe, Parving, Hans-Henrik, Keane, William F, Zhang, Zhongxin, Shahinfar, Shahnaz, Snapinn, Steve, Cooper, Mark E, Mitch, William E, Brenner, Barry M

“…Albuminuria is an established risk marker for both cardiovascular and renal outcomes. Albuminuria can be reduced with drugs that block the renin-angiotensin…”
Get full text

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL by de Zeeuw, Dick, Remuzzi, Giuseppe, Parving, Hans-Henrik, Keane, William F., Zhang, Zhongxin, Shahinfar, Shahnaz, Snapinn, Steve, Cooper, Mark E., Mitch, William E., Brenner, Barry M.

“…Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Proteinuria or albuminuria is an established risk…”
Get full text

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy by Brenner, Barry M, Cooper, Mark E, de Zeeuw, Dick, Keane, William F, Mitch, William E, Parving, Hans-Henrik, Remuzzi, Giuseppe, Snapinn, Steven M, Zhang, Zhonxin, Shahinfar, Shahnaz

“…Angiotensin-receptor blockade may delay the onset of end-stage renal disease and ameliorate heart failure in patients with type 2 diabetes. Interruption of the…”
Get full text

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study by Kurokawa, Kiyoshi, Chan, Juliana C N, Cooper, Mark E, Keane, William F, Shahinfar, Shahnaz, Zhang, Zhongxin

“…The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study has previously shown losartan to confer significant benefits to…”
Get full text

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study by Keane, William F., Brenner, Barry M., de Zeeuw, Dick, Grunfeld, Jean-Pierre, McGill, Janet, Mitch, William E., Ribeiro, Artur B., Shahinfar, Shahnaz, Simpson, Roger L., Snapinn, Steven M., Toto, Robert, RENAAL Study Investigators

“…The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Diabetic nephropathy has become the single…”
Get full text

Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy by Mohanram, Anupama, Zhang, Zhongxin, Shahinfar, Shahnaz, Keane, William F., Brenner, Barry M., Toto, Robert D.

“…Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Diabetic nephropathy is the leading cause of end-stage renal disease…”
Get full text